{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"UFPT","limit":50},"count":50,"signals":[{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":107,"context":"mers for a large percentage of our net sales. The loss of any such customer, a reduction in net sales to any such customer, or the decline in the financial condition of any such customer could have a material adverse effect on our business, financial condition, and results of operations. Seasonality is not a major factor in the Companys net sales. See the Companys consolidated financial statements contained in Part IV,","filed_date":"2026-02-27","accession":"0001628280-26-012816","full_text":"https://origin.rootz.global/static/filing/0001628280-26-012816.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ted not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o | | | | Item 1.05 Material Cybersecurity Incidents.On or about February 14, 2026, UFP Technologies, Inc. (the Company) detected suspicious activity involving its information technology (IT) systems. Upon detecting the issue, the Com","filed_date":"2026-02-24","accession":"0001628280-26-011152","full_text":"https://origin.rootz.global/static/filing/0001628280-26-011152.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":67,"context":"ach to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a nonbinding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To vote on a non-binding advisory resolution on the frequency of future advisory votes on the compensation of our named executive officers; | | | | 4. | To ratify the appointme","filed_date":"2025-04-30","accession":"0001171843-25-002638","full_text":"https://origin.rootz.global/static/filing/0001171843-25-002638.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":53,"context":"mers for a large percentage of our net sales. The loss of any such customer, a reduction in net sales to any such customer, or the decline in the financial condition of any such customer could have a material adverse effect on our business, financial condition, and results of operations. Seasonality is not a major factor in the Companys net sales. See the Companys consolidated financial statements contained in Part IV,","filed_date":"2025-03-03","accession":"0001171843-25-001192","full_text":"https://origin.rootz.global/static/filing/0001171843-25-001192.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"together with any additional amounts required pursuant to Section 3.05. Each prepayment of the outstanding Term Loans pursuant to this Section 2.05(a) shall be applied to the principal repayment installments thereof in inverse order of maturity. Subject to Section 2.15, such prepayments shall be paid to the Lenders in accordance with their respective Applicable Percentages in respect of each of the r","filed_date":"2024-07-01","accession":"0001171843-24-003738","full_text":"https://origin.rootz.global/static/filing/0001171843-24-003738.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"on and Power. | 88 | | | 5.02Authorization; No Contravention. | 88 | | | 5.03Governmental Authorization; Other Consents. | 88 | | | 5.04Binding Effect. | 89 | | | 5.05Financial Statements; No Material Adverse Effect. | 89 | | | 5.06Litigation. | 89 | | | 5.07No Default. | 90 | | | 5.08Ownership of Property. | 90 | | | 5.09Environmental Matters. | 90 | | | 5.10Insurance. | 90 | | | 5.11Taxes. | 90 |","filed_date":"2024-07-01","accession":"0001171843-24-003738","full_text":"https://origin.rootz.global/static/filing/0001171843-24-003738.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":66,"context":"ach to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a nonbinding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2024; and | | | | 4. | To transact s","filed_date":"2024-04-26","accession":"0001171843-24-002290","full_text":"https://origin.rootz.global/static/filing/0001171843-24-002290.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":49,"context":"customers for a large percentage of our revenues. The loss of any such customer, a reduction in sales to any such customer, or the decline in the financial condition of any such customer could have a material adverse effect on our business, financial condition, and results of operations. 5 Seasonality is not a major factor in the Companys sales. See the Companys consolidated financial statements contained in Part IV, It","filed_date":"2024-02-29","accession":"0001171843-24-001078","full_text":"https://origin.rootz.global/static/filing/0001171843-24-001078.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":66,"context":"2024 Annual Meeting of Stockholders and until their successors are duly elected; | |   |   | 2. | To vote on a non‑binding advisory resolution to approve the compensation of our named executive officers; | |   |   | 3. | To consider the proposed amendment and restatement of the Company’s Certificate of Incorporation to provide limited exculpation to the Company’s officer","filed_date":"2023-04-25","accession":"0001171843-23-002531","full_text":"https://origin.rootz.global/static/filing/0001171843-23-002531.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":25,"context":"with its suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Company’s business.   **Research and Development**   The Company’s engineering personnel continuously explore design and manufacturing techniques, as well as new and in","filed_date":"2023-03-16","accession":"0001171843-23-001734","full_text":"https://origin.rootz.global/static/filing/0001171843-23-001734.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"e ordinary course of business. In the opinion of management of the Company, these suits, claims and complaints should not result in final judgments or settlements that, in the aggregate, would have a material adverse effect on the Company’s financial condition or results of operations.   **ITEM 1A:** ****    **RISK FACTORS**   The Company faces a number of uncertainties and risk","filed_date":"2022-05-10","accession":"0001171843-22-003511","full_text":"https://origin.rootz.global/static/filing/0001171843-22-003511.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":63,"context":", each to serve until the 2023 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a nonbinding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To consider and act upon a proposal to amend and restate the Companys 2009 Non-Employee Director Stock Option Incentive Plan. | | | | 4. | To ratify the appointment of Grant Thornton","filed_date":"2022-04-29","accession":"0001171843-22-003002","full_text":"https://origin.rootz.global/static/filing/0001171843-22-003002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"with its suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Company’s business.   **Research and Development**   The Company’s engineering personnel continuously explore design and manufacturing techniques, as well as new and in","filed_date":"2022-03-14","accession":"0001171843-22-001850","full_text":"https://origin.rootz.global/static/filing/0001171843-22-001850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"together with any additional amounts required pursuant to Section 3.05. Each prepayment of the outstanding Term Loans pursuant to this Section 2.05(a) shall be applied to the principal repayment installments thereof in inverse order of maturity. Subject to Section 2.15, such prepayments shall be paid to the Lenders in accordance with their respective Applicable Percentages in respect of each of the r","filed_date":"2021-12-23","accession":"0001171843-21-008678","full_text":"https://origin.rootz.global/static/filing/0001171843-21-008678.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":33,"context":"on and Power. | 80 | | | 5.02Authorization; No Contravention. | 80 | | | 5.03Governmental Authorization; Other Consents. | 80 | | | 5.04Binding Effect. | 80 | | | 5.05Financial Statements; No Material Adverse Effect. | 80 | | | 5.06Litigation. | 81 | | | 5.07No Default. | 81 | | | | ii | | | | 5.08Ownership of Property. | 82 | | | 5.09Environmental Matters. | 82 | | | 5.10Insurance. | 82 | | | 5.11Ta","filed_date":"2021-12-23","accession":"0001171843-21-008678","full_text":"https://origin.rootz.global/static/filing/0001171843-21-008678.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":62,"context":"each to serve until the 2022 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To amend and restate our 2003 Equity Incentive Plan to ratify the continued issuance of incentive stock options under the plan and conform the plan to certain changes in the U.S. Tax","filed_date":"2021-05-05","accession":"0001171843-21-003167","full_text":"https://origin.rootz.global/static/filing/0001171843-21-003167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"with its suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Company’s business.   **Research and Development**   The Company’s engineering personnel continuously explore design and manufacturing techniques, as well as new and in","filed_date":"2021-03-12","accession":"0001171843-21-001724","full_text":"https://origin.rootz.global/static/filing/0001171843-21-001724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":58,"context":"nate the classified structure of our Board of Directors and provide for the annual election of directors; | | | | 3. | To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; | | | | 4. | To ratify the appointment of Grant Thornton LLP as the Companys independent registered public accounting firm; and | | | | 5. | To transact such other business as may properly come b","filed_date":"2020-04-28","accession":"0001171843-20-002935","full_text":"https://origin.rootz.global/static/filing/0001171843-20-002935.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"with its suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. ** ** **Research and Development** ** ** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new and innovative materials","filed_date":"2020-03-13","accession":"0001171843-20-001695","full_text":"https://origin.rootz.global/static/filing/0001171843-20-001695.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":57,"context":"ement to serve until the 2022 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To vote on a non-binding advisory resolution on the frequency of future advisory votes on the compensation of our named executive officers; | | | | 4. | To ratify the appointment of","filed_date":"2019-04-26","accession":"0001171843-19-002676","full_text":"https://origin.rootz.global/static/filing/0001171843-19-002676.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ith their suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. ** ** **Research and Development** ** ** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new and innovative materials","filed_date":"2019-03-15","accession":"0001171843-19-001752","full_text":"https://origin.rootz.global/static/filing/0001171843-19-001752.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":67,"context":"ement to serve until the 2021 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To ratify the appointment of Grant Thornton LLP as the Companys independent registered public accounting firm; and | | | | 4. | To transact such other business as may properly come b","filed_date":"2018-04-25","accession":"0001171843-18-003028","full_text":"https://origin.rootz.global/static/filing/0001171843-18-003028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":34,"context":"| 5.02 | Authorization; No Contravention | 67 | | | | 5.03 | Governmental Authorization; Other Consents | 67 | | | | 5.04 | Binding Effect | 67 | | | | 5.05 | Financial Statements; No Material Adverse Effect | 68 | | | | 5.06 | Litigation | 68 | | | | 5.07 | No Default | 68 | | | | 5.08 | Ownership of Property | 69 | | | | 5.09 | Environmental Compliance | 69 | | | | 5.1 | Insurance |","filed_date":"2018-03-16","accession":"0001171843-18-002024","full_text":"https://origin.rootz.global/static/filing/0001171843-18-002024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":67,"context":"ement to serve until the 2020 Annual Meeting of Stockholders and until their successors are duly elected; | | | | 2. | To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; | | | | 3. | To ratify the appointment of Grant Thornton LLP as the Companys independent registered public accounting firm; and | | | | 4. | To transact such other business as may properly come b","filed_date":"2017-04-28","accession":"0001171843-17-002417","full_text":"https://origin.rootz.global/static/filing/0001171843-17-002417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":21,"context":"3.0 | % | | | 73.5 | % | | | Gross profit | | | 23.7 | % | | | 27.0 | % | | | 26.5 | % | | | Selling, general, and administrative expenses | | | 16.5 | % | | | 17.3 | % | | | 17.1 | % | | | Restructuring costs | | | 0.3 | % | | | 1.3 | % | | | 1.1 | % | | | Material overcharge settlement | | | -1.4 | % | | | 0.0 | % | | | 0.0 | % | | | (Gain) loss on sale of property, plant and equipment | | | 0.0","filed_date":"2017-03-10","accession":"0001171843-17-001409","full_text":"https://origin.rootz.global/static/filing/0001171843-17-001409.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"with such suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. **Research and Development** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new, innovative materials to meet the un","filed_date":"2017-03-10","accession":"0001171843-17-001409","full_text":"https://origin.rootz.global/static/filing/0001171843-17-001409.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"| | Gross profit | | | 8,452 | | | | 9,510 | | | | 26,465 | | | | 28,442 | | | | Selling, general & administrative expenses | | | 6,027 | | | | 5,604 | | | | 18,402 | | | | 18,404 | | | | Restructuring costs | | | 25 | | | | 851 | | | | 203 | | | | 959 | | | | Material overcharge settlement | | | (1,681 | ) | | | - | | | | (2,114 | ) | | | - | | | | Gain on sale of fixed assets | | | - | | |","filed_date":"2016-11-09","accession":"0001171843-16-013061","full_text":"https://origin.rootz.global/static/filing/0001171843-16-013061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"rofit | | | 10,295 | | | 10,293 | | | 18,022 | | | 18,932 | | | | Selling, general, and administrative expenses | | | 6,470 | | | 6,776 | | | 12,374 | | | 12,800 | | | | Restructuring costs | | | 55 | | | 30 | | | 178 | | | 108 | | | | Material overcharge settlement | | | (423) | | | — | | | (423) | | | — | | | | Gain on sale of fixed assets |","filed_date":"2016-08-09","accession":"0001558370-16-007734","full_text":"https://origin.rootz.global/static/filing/0001558370-16-007734.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":71,"context":"proposal to approve the material terms of the performance goals under the Company's 2003 Incentive Plan, as amended; 3.To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; 4.To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm; and 5.To transact such other business as may properly come before the annual meetin","filed_date":"2016-04-29","accession":"0001047469-16-012747","full_text":"https://origin.rootz.global/static/filing/0001047469-16-012747.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":20,"context":"to optimize its footprint, implement new enterprise resource planning software and expend its team of engineers. As part of this, the Company expects to incur a total of approximately $2.1 million in restructuring costs associated with consolidating operations in the Northeast, of which approximately $1.7 million has been incurred through December 31, 2015. As a result of these consolidations, it anticipates annual","filed_date":"2016-03-11","accession":"0001104659-16-104377","full_text":"https://origin.rootz.global/static/filing/0001104659-16-104377.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"with such suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. **Research and Development** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new, innovative materials to meet the un","filed_date":"2016-03-11","accession":"0001104659-16-104377","full_text":"https://origin.rootz.global/static/filing/0001104659-16-104377.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":70,"context":"g proxy statement to serve until the 2018 Annual Meeting of Stockholders and until their successors are duly elected; 2.To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; 3.To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm; and 4.To transact such other business as may properly come before the annual meetin","filed_date":"2015-04-29","accession":"0001047469-15-004127","full_text":"https://origin.rootz.global/static/filing/0001047469-15-004127.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"with such suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. Research and Development** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new innovative materials to meet the uniqu","filed_date":"2015-03-13","accession":"0001104659-15-019457","full_text":"https://origin.rootz.global/static/filing/0001104659-15-019457.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":69,"context":"g proxy statement to serve until the 2017 Annual Meeting of Stockholders and until their successors are duly elected; 2.To vote on a non-binding advisory resolution to approve the compensation of our named executive officers; 3.To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm; and 4.To transact such other business as may properly come before the annual meetin","filed_date":"2014-04-30","accession":"0001047469-14-004447","full_text":"https://origin.rootz.global/static/filing/0001047469-14-004447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"with such suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for these foams. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. **Research and Development** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new innovative materials to meet the uni","filed_date":"2014-03-14","accession":"0001104659-14-019572","full_text":"https://origin.rootz.global/static/filing/0001104659-14-019572.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":52,"context":"a facility for $1,250,000. The net book value of the asset at December 31, 2010, was approximately $384,000. Selling expenses of approximately $38,000 were incurred. On February 29, 2012, the Company purchased from UDT for $1,350,000 the Florida manufacturing building that the Company had previously leased. The purchase price approximates fair market value based upon appraisals done by independent professional firms. As","filed_date":"2013-04-30","accession":"0001047469-13-005171","full_text":"https://origin.rootz.global/static/filing/0001047469-13-005171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"uch suppliers are good, and the Company expects that these suppliers will be able to meet its requirements for cross-linked foam. Any delay or interruption in the supply of raw materials could have a material adverse effect on the Companys business. **Research and Development** The Companys engineering personnel continuously explore design and manufacturing techniques, as well as new innovative materials to meet the uni","filed_date":"2013-03-15","accession":"0001104659-13-020973","full_text":"https://origin.rootz.global/static/filing/0001104659-13-020973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":36,"context":"a facility for $1,250,000. The net book value of the asset at December 31, 2010, was approximately $384,000. Selling expenses of approximately $38,000 were incurred. On February 29, 2012, the Company purchased from UDT for $1,350,000 the Florida manufacturing building that the Company had previously leased. The purchase price approximates fair market value based upon appraisals done by independent professional firms. As","filed_date":"2012-04-27","accession":"0001047469-12-004940","full_text":"https://origin.rootz.global/static/filing/0001047469-12-004940.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"al sales for the year ended December 31, 2011. No one customers sales exceeded 10% of the Packaging segment sales for the year ended December 31, 2011. The loss of Recticel as a customer could have a material adverse effect on the Company. **Manufacturing** The Companys manufacturing operations consist primarily of cutting, molding, vacuum-forming, laminating, and assembling. For custom-molded foam products, the Company","filed_date":"2012-03-15","accession":"0001104659-12-018476","full_text":"https://origin.rootz.global/static/filing/0001104659-12-018476.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":38,"context":"any's website, www.ufpt.com. Under the provisions of the Compensation Committee Charter, the primary functions of the Compensation Committee include determining salaries and bonuses for the Company's named executive officers, individuals to whom stock options, other equity-based awards and cash awards are granted, and the terms upon which such grants and awards are made, adopting incentive plans, overseeing risks associ","filed_date":"2011-04-29","accession":"0001047469-11-004292","full_text":"https://origin.rootz.global/static/filing/0001047469-11-004292.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"al sales for the year ended December 31, 2010. No one customers sales exceeded 10% of the Packaging segment sales for the year ended December 31, 2010. The loss of Recticel as a customer could have a material adverse effect on the Company. **Manufacturing** The Companys manufacturing operations consist primarily of cutting, molding, vacuum-forming, laminating, and assembling. For custom-molded foam products, the Company","filed_date":"2011-03-16","accession":"0001104659-11-014612","full_text":"https://origin.rootz.global/static/filing/0001104659-11-014612.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":38,"context":"at the Company's website, www.ufpt.com. Under the provisions of the Compensation Committee Charter, the primary functions of the Compensation Committee include determining salaries for the Company's named executive officers, individuals to whom stock options, other equity awards and cash awards are granted, and the terms upon which such grants and awards are made, incentive plans, oversight of risks associated with the","filed_date":"2010-04-30","accession":"0001047469-10-004555","full_text":"https://origin.rootz.global/static/filing/0001047469-10-004555.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":", comprised 10.6% of that segments total sales and 4.1% of the Companys total sales for the year ended December 31, 2009. The loss of either Recticel or Stephen Gould Corp. as a customer could have a material adverse effect on the Company. ### Manufacturing ### The Companys manufacturing operations consist primarily of cutting, molding, vacuum forming, laminating, and assembling. For custom molded foam products, the Co","filed_date":"2010-03-30","accession":"0001104659-10-017240","full_text":"https://origin.rootz.global/static/filing/0001104659-10-017240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"e ordinary course of business. In the opinion of management of the Company, these suits, claims and complaints should not result in final judgments or settlements that, in the aggregate, would have a material adverse effect on the Companys financial condition or results of operations.ITEM 1A:RISK FACTORSThe Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of t","filed_date":"2026-08-06","accession":"0001628280-26-054428","full_text":"https://origin.rootz.global/static/filing/0001628280-26-054428.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":96,"match_count":12,"context":"0 | % | | | 23.7 | % | | | Selling, general, and administrative expenses | | | 14.6 | % | | | 16.1 | % | | | 16.5 | % | | | Acquisition costs | | | 0.6 | % | | | 0.0 | % | | | 0.0 | % | | | Restructuring costs | | | 0.0 | % | | | 0.0 | % | | | 0.3 | % | | | Material overcharge settlement | | | -0.1 | % | | | -0.1 | % | | | -1.4 | % | | | Operating income | | | 10.3 | % | | | 8.0 | % | | | 8.3 |","filed_date":"2019-03-15","accession":"0001171843-19-001752","full_text":"https://origin.rootz.global/static/filing/0001171843-19-001752.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"it Guaranty Corporation. Pension Act means the Pension Protection Act of 2006. Pension Funding Rules means the rules of the Code and ERISA regarding minimum required contributions (including any installment payment thereof) to Pension Plans and set forth in, with respect to plan years ending prior to the effective date of the Pension Act, Section 412 of the Code and Section 302 of ERISA, each as in e","filed_date":"2018-03-16","accession":"0001171843-18-002024","full_text":"https://origin.rootz.global/static/filing/0001171843-18-002024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":96,"match_count":12,"context":"| | 75,566 | | | | Gross profit | | 9,510 | | 9,752 | | 28,442 | | 28,474 | | | | Selling, general & administrative expenses | | 5,604 | | 5,940 | | 18,404 | | 18,368 | | | | Restructuring costs | | 851 | | 772 | | 959 | | 1,096 | | | | Gain on sale of fixed assets | | | | (58 | ) | (31 | ) | (70 | ) | | | Operating income | | 3,055 | | 3,098 | | 9,110 | | 9,080 |","filed_date":"2015-11-06","accession":"0001104659-15-076459","full_text":"https://origin.rootz.global/static/filing/0001104659-15-076459.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":96,"match_count":12,"context":"73.5 | % | 70.5 | % | 70.7 | % | | | Gross profit | | 26.5 | % | 29.5 | % | 29.3 | % | | | Selling, general, and administrative expenses | | 17.1 | % | 17.0 | % | 16.5 | % | | | Restructuring costs | | 1.1 | % | 0.0 | % | 0.0 | % | | | (Gain) loss on sale of fixed assets | | 0.0 | % | 0.0 | % | 0.0 | % | | | Operating income | | 8.3 | % | 12.5 | % | 12.8 | % | | | Total","filed_date":"2015-03-13","accession":"0001104659-15-019457","full_text":"https://origin.rootz.global/static/filing/0001104659-15-019457.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":88,"match_count":11,"context":"| | 49,912 | | | | Gross profit | | 10,293 | | 9,545 | | 18,932 | | 18,722 | | | | Selling, general & administrative expenses | | 6,776 | | 6,535 | | 12,800 | | 12,428 | | | | Restructuring costs | | 30 | | 234 | | 108 | | 324 | | | | Gain on sale of fixed assets | | | | (12 | ) | (31 | ) | (12 | ) | | | Operating income | | 3,487 | | 2,788 | | 6,055 | | 5,982 | |","filed_date":"2015-08-07","accession":"0001104659-15-057453","full_text":"https://origin.rootz.global/static/filing/0001104659-15-057453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"UFPT","company":"UFP TECHNOLOGIES INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":88,"match_count":11,"context":"| | 49,908 | | | | Gross profit | | 9,476 | | 10,719 | | 18,584 | | 19,621 | | | | Selling, general & administrative expenses | | 6,466 | | 6,075 | | 12,290 | | 12,021 | | | | Restructuring costs | | 234 | | | | 324 | | | | | | (Gain) loss on sale of fixed assets | | (12 | ) | 11 | | (12 | ) | 11 | | | | Operating income | | 2,788 | | 4,633 | | 5,982 | | 7,589 | |","filed_date":"2014-08-08","accession":"0001104659-14-058621","full_text":"https://origin.rootz.global/static/filing/0001104659-14-058621.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"53f802f93041359a6ddfa233fcd4090e61a80fae1a7a70b3adc7bd08ee6fe993","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7a9dae843f4801dc87550af30e5ccc2b9100a1ce6c106b4d0e29d65281313dff","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":451,"hourly_limit":500,"remaining":49,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}